Page 29 - Gates-AnnualReport-2015

GRAND OPENING APRIL 6, 2015
New Aurora medical production lab could keep top Anschutz talent from going elsewhere.
Researchers at the University of Colorado Anschutz Medical Campus cut the ribbon on a new on-campus facility April 6 that is expected to thrust Aurora’s health mecca to the national forefront of adult stem cell and protein- based biologic research.
- Aurora Biz AURORA | April 8, 2015
The vision of the Gates family is being realized at the Gates Center,
which took a giant step forward last month when it opened the Gates Biomanufacturing Facility. It not only will help provide cell-based therapies for patients with cancer, cardiovascular disease, HIV, influenza, skin diseases and others, but also furthers CU Anschutz as one of the world’s leading academic medical facilities and a major health care destination. Fittingly, one of the cell-based therapies being developed at the facility will help address the macular degeneration that afflicted my friend Charlie Gates.
-University of Colorado President Bruce Benson, May 10, 2015
Within one week of the grand opening, the Gates Biomanufacturing Facility began performing process development services for a publicly traded pharmaceutical company based in Colorado. By year’s end 2015, the facility had performed process development services for three different companies and two CU Anschutz Medical Campus researchers. This early customer activity underscored the anticipated urgency for such a facility. Going into 2016, our staff was in discussions with a number of qualified prospects who were interested in both process development and cGMP production.
Gates Biomanufacturing Facility Oversight Committee and staff: (BACK ROW, left to right) Patrick Gaines, Erin
O’Brien, Gabe Orosco, Tom Payne, Wag Schorr, Tim Gardner, Don Elliman, Alison Lakin (FRONT ROW, left to right)
Dennis Roop, Matt Seefeldt, Jill Cowperthwaite, Jena Hausmann (not pictured: Terri Carrothers, Will Cook, Neil
Krauss and Steve VanNurden)
Gates Center for Regenerative Medicine 29